Miss our 2020 MIPS Reporting Webinar on 10/22? Click here to play it back!

2019 MIPS Cost: Revascularization for Lower Extremity Chronic Critical Limb Ischemia Measure

Introduction

This document details the methodology for the Revascularization for Lower Extremity Chronic Critical Limb Ischemia measure and should be reviewed along with the Revascularization for Lower Extremity Chronic Critical Limb Ischemia Measure Codes List file, which contains the medical codes used in constructing the measure.

Detailed PDF Download

 

Measure Description

Episode-based cost measures represent the cost to Medicare for the items and services provided to a patient during an episode of care (“episode”). In all supplemental documentation, “cost” generally means the standardized Medicare allowed amount, which includes both Medicare and trust fund payments and any applicable beneficiary deductible and coinsurance amounts.1,2

The Revascularization for Lower Extremity Chronic Critical Limb Ischemia episode-based cost measure evaluates a clinician’s risk-adjusted cost to Medicare for beneficiaries who undergo elective revascularization surgery for lower extremity chronic critical limb ischemia during the performance period. The cost measure score is the clinician’s risk-adjusted cost for the episode group averaged across all episodes attributed to the clinician. This procedural measure includes costs of services that are clinically related to the attributed clinician’s role in managing care during each episode from 30 days prior to the clinical event that opens, or “triggers,” the episode through 90 days after the trigger.

 

Measure Rationale

Roughly 8.5 million people in the United States are affected by Peripheral Vascular Disease (PVD), and the total costs from PVD in the United States are around $21 billion annually.3 Surgeries associated with Revascularization for Lower Extremity Chronic Critical Limb Ischemia are fairly common, and there are significant opportunities for improvement in care for this patient population. The Revascularization for Lower Extremity Chronic Critical Limb Ischemia episode-based cost measure was recommended for development by an expert clinician committee—the Peripheral Vascular Disease Management Clinical Subcommittee—because of its high impact in terms of patient population and Medicare spending, and the opportunity for incentivizing cost-effective, high-quality clinical care in this area. The Clinical Subcommittee provided extensive, detailed input on this measure.

 

Measure Numerator

The cost measure numerator is the sum of the ratio of observed to expected4 payment-standardized cost to Medicare for all Revascularization for Lower Extremity Chronic Critical Limb Ischemia episodes attributed to a clinician. This sum is then multiplied by the national average observed episode cost to generate a dollar figure.

 

Measure Denominator

The cost measure denominator is the total number of episodes from the Revascularization for Lower Extremity Chronic Critical Limb Ischemia episode group attributed to a clinician.

 

Data Sources

The Revascularization for Lower Extremity Chronic Critical Limb Ischemia cost measure uses the following data sources:

  • Medicare Parts A and B claims data from the Common Working File (CWF)
  • Enrollment Data Base (EDB)
  • Long Term Care Minimum Data Set (LTC MDS)

 

Care Settings

Methodologically, the Revascularization for Lower Extremity Chronic Critical Limb Ischemia cost measure can be triggered based on claims data from the following settings: ambulatory surgical centers (ASC), hospital outpatient departments (HOPD), and inpatient (IP) hospitals.

 

Cohort

The cohort for this cost measure consists of patients who are Medicare beneficiaries enrolled in Medicare fee-for-service and who undergo elective revascularization surgery for lower extremity chronic critical limb ischemia that triggers a Revascularization for Lower Extremity Chronic Critical Limb Ischemia episode.
The cohort for this cost measure is also further refined by the definition of the episode group and measure-specific exclusions (see Section 3.0).

--------------------

1 - Claims data from Medicare Parts A and B are used to construct the episode-based cost measures.
2 - Claim payments are standardized to account for differences in Medicare payments for the same service(s) across Medicare providers. Payment standardized costs remove the effect of differences in Medicare payment among health care providers that are the result of differences in regional health care provider expenses measured by hospital wage indexes and geographic price cost indexes (GPCIs) or other payment adjustments such as those for teaching hospitals. For more information, please refer to the “CMS Price (Payment) Standardization - Basics" and “CMS Price (Payment) Standardization - Detailed Methods” documents posted on QualityNet: http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic/P...
3 - CDC. “Peripheral Arterial Disease (PAD) Fact Sheet.” https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_pad.htm
4 - Expected costs refer to costs predicted by the risk adjustment model. For more information on expected costs and risk adjustment, please refer to Section 3.5.

 

Register with MDinteractive